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Abstract
AIM
To evaluate the occurrence of resistant mutations in 
treatment-naïve hepatitis C virus (HCV) sequences 
deposited in the European hepatitis C virus database 
(euHCVdb). 
METHODS
The sequences were downloaded from the euHCVdb 
(https://euhcvdb.ibcp.fr/euHCVdb/). The search was 
performed for full-length NS3 protease, NS5A and NS5B 
polymerase sequences of HCV, separated by genotypes 
1a, 1b, 2a, 2b and 3a, and resulted in 798 NS3, 708 
NS5A and 535 NS5B sequences from HCV genotypes 
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1a, 1b, 2a, 2b and 3a, after the exclusion of sequences 
containing errors and/or gaps or incomplete sequences, 
and sequences from patients previously treated with 
direct antiviral agents (DAA). The sequence alignment 
was performed with MEGA 6.06 MAC and the resulting 
protein sequences were then analyzed using the BioEdit 
7.2.5. for mutations associated with resistance. Only 
positions that have been described as being associated 
with failure in treatment in in vivo  studies, and/or as 
conferring a more than 2-fold change in replication in 
comparison to the wildtype reference strain in in vitro  
phenotypic assays were included in the analysis.
RESULTS
The Q80K variant in the NS3  gene was the most 
prevalent mutation, being found in 44.66% of subtype 
1a and 0.25% of subtype 1b. Other frequent mutations 
observed in more than 2% of the NS3 sequences 
were: I170V (3.21%) in genotype 1a, and Y56F 
(15.93%), V132I (23.28%) and I170V (65.20%) in 
genotype 1b. For the NS5A, 2.21% of the genotype 
1a sequences have the P58S mutation, 5.95% of 
genotype 1b sequences have the R30Q mutation, 
15.79% of subtypes 2a sequences have the Q30R 
mutation, 23.08% of subtype 2b sequences have a 
L31M mutation, and in subtype 3a sequences, 23.08% 
have the M31L resistant variants. For the NS5B, the 
V321L RAV was identified in 0.60% of genotype 1a 
and in 0.32% of genotype 1b sequences, and the 
N142T variant was observed in 0.32% of subtype 
1b sequences. The C316Y, S556G, D559N RAV were 
identified in 0.33%, 7.82% and 0.32% of genotype 1b 
sequences, respectively, and were not observed in other 
genotypes.
CONCLUSION
HCV mutants resistant to DAAs are found in low 
frequency, nevertheless they could be selected and 
therapy could fail due resistance substitutions in HCV 
genome.
Key words: Hepatitis C virus resistance; Quasispecies; 
Direct antiviral agents; Polymorphisms; Drug resistance
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Chronic hepatitis C virus (HCV) infection is 
a significant cause of morbidity and mortality. The 
main therapeutic targets are the NS3/4A protease, 
NS5B polymerase, and NS5A replication complex. 
Pre-existence of resistance associated variants to 
direct antiviral agents (DAA) reduces sustained 
virologic response rates. Despite the low frequency 
of mutations, this resistant population is likely to be 
selected in patients undergoing therapy with DAA. 
Even though HCV variants resistant to DAA targeting 
one viral protein remain susceptible to DAA targeting 
another viral protein, combination therapy could fail 
due to selection of HCV with resistance substitutions in 
multiple targets.
Kliemann DA, Tovo CV, da Veiga ABG, de Mattos AA, Wood 
C. Polymorphisms and resistance mutations of hepatitis C virus 
on sequences in the European hepatitis C virus database. World 
J Gastroenterol 2016; 22(40): 8910-8917  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i40/8910.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i40.8910
INTRODUCTION
Chronic hepatitis C virus (HCV) infection affects around 
180 million people worldwide and is a significant cause 
of liver-related morbidity and mortality[1] until recently. 
Interferon-α in combination with Ribavirin was the 
mainstream treatment regimen but eligibility and 
safety of the interferon-based therapies were low, and 
consequently the overall effectiveness of the treatment 
was very limited. Fortunately, the development of new 
direct-acting antiviral (DAA) drugs against HCV has 
progressed significantly and resulted in oral interferon-
free therapies[2].
The three main therapeutic targets for HCV infection 
are the NS3/4A protease, the NS5B polymerase, 
and the NS5A replication complex. The first series 
of interferon-free regimens, including combinations 
of simeprevir (SMV), sofosbuvir (SOF), paritaprevir, 
daclatasvir, ledipasvir (LDV), ombitasvir (OMV), 
dasabuvir (DSV), grazoprevir (GZR) and elbasvir have 
already been approved and recommended by the 
European Association for the Study of the Liver (EASL) 
and by the American Association for the Study of Liver 
Diseases (AASLD)[3,4].
HCV variants infecting the human population show 
extreme genetic diversity, which is partly explained by 
the long evolutionary association between the virus 
and its human host. HCV exists in the host as a swarm 
of related quasispecies. This diversity is a result of 
the error-prone viral polymerase combined with rapid 
viral replication, which, in turn, enables the virus to 
rapidly overcome the host immune responses and to 
become resistant to antiviral drugs[5]. The selection of 
resistance-associated amino-acid variants (RAV) from 
HCV quasispecies is dependent on drug-, host- and 
virus-related factors. The potency of the drug itself is 
primarily influenced by viral susceptibility, by previous 
exposure to the drug and by the genetic barrier to 
resistance. The ability of a RAV to persist and to induce 
treatment failure (relapse, non-response or viral 
breakthrough) is related to its fitness or its replication 
capacity as compared to the wild-type virus[6,7].
Resistance to DAAs is driven by the selection of 
mutations at different positions in the NS3 protease, 
NS5B polymerase and NS5A protein[8,9]. Each compound 
or drug family induces a specific mutation profile that 
may be characteristic of the viral genotype/subtype. 
Furthermore, each class of DAA is characterized by a 
difference in the genetic barrier to resistance. Even 
though the specific resistance mutation for each 
individual agent in the drug class differs, there is a 
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great concern about the possibility of cross-resistance 
between compounds in the same inhibitor class, 
especially for the NS3 protease and NS5A inhibitors[10].
The ability to detect RAV depends primarily on 
the different types of the sequencing technologies 
used, including population-based sequencing, clonal 
sequencing and deep sequencing. The sensitivities for 
detection by these three approaches were reported to 
be approximately 25%, 5% and 0.5%, respectively, 
and the presence of viral mutants below the detection 
levels might be missed[11]. For HCV the frequency 
of routine testing of drug resistance prior to the use 
of the new treatment regimens is not known. Some 
guidelines[4] suggest that routine monitoring for HCV 
drug resistance-associated variants during therapy 
should not be recommended and there is no consensus 
on the utility of pre-treatment resistance testing.
Currently, there is a large number of HCV sequ-
ences available on public databanks, however they 
have not been analyzed to correlate HCV genotypes 
and viral genomic characteristics with drug resistance 
phenotypes[11]. Three HCV databases are currently 
available to provide insight into the basic biology, 
immunology, and evolution of the virus: the Japanese 
database (http://s2as02.genes.nig.ac.jp), the 
European database (http://euhcvdb.ibcp.fr) and the 
American database (Los Alamos National Laboratory) 
(http://hcv.lanl.gov).
The objective of this study is to evaluate the 
occurrence of polymorphisms and resistant mutations 
in the NS3, NS5A and NS5B regions in treatment-naïve 
HCV sequences deposited in the European hepatitis C 
virus database (euHCVdb). This analysis will provide 
insights into the levels of circulating drug resistance, 
which may affect the success of the therapeutic 
regimens.
MATERIALS AND METHODS
HCV database
The sequences were downloaded from the euHCVdb 
(https://euhcvdb.ibcp.fr/euHCVdb/). This bank 
provides important data about the HCV sequences 
(e.g. genotype, genomic region, viral proteins and 
their functions, known 3-dimensional structures) and 
ensures consistency of the annotations, which enables 
reliable keyword queries. Users can extract subsets of 
sequences obtained by Sanger sequencing matching 
particular criteria or enter their own sequences and 
analyze them with various bioinformatics programs 
available on the same server. The euHCVdb is mainly 
oriented towards protein sequence, structure and 
function analyses and structural biology of HCV, and is 
re-built every month from an up-to-date database by 
an automated process[12]. 
The search was performed for full-length NS3 
protease, NS5A and NS5B polymerase sequences of 
HCV separated by genotypes 1a, 1b, 2a, 2b and 3a. 
These subtypes were chosen due to their worldwide 
prevalence and presence in drug trials, specifically 
genotype 1 with protease inhibitors (PI) and genotype 
3 with polymerase inhibitor. Reference strains for the 
three genotypes were obtained (1a: AF009606, 1b: 
D90208, 2a: D00944, 2b: D10988 and 3a: D17763). 
Sequences containing missing data, such as gaps 
and sequencing errors, and sequences from patients 
previously treated with DAA were excluded from 
the analysis. To ensure the quality of the analysis, 
sequences with stop codons in the NS5B gene or 
with ambiguities consisting of more than 2 bases per 
nucleotide position or more than 2 ambiguities per 
codon at individual drug resistance-associated position 
were also excluded.
Alignment and edition of the sequences
The sequence alignment was performed with MEGA 
6.06 MAC[13] followed by sequence editing, exclusion 
of sequences with missing data, and translation of 
the nucleic acids sequences into amino acids. The 
resulting protein sequences were then analyzed using 
BioEdit 7.2.5. to identify mutations associated with 
resistance[14].
Analysis of natural polymorphisms
Known mutations associated with resistance to 
protease-, NS5A complex- and polymerase-inhibitors 
were used to search for polymorphism patterns among 
HCV genotypes[15]. Only positions that have been 
described as being associated with failure in treatment 
in in vivo studies, and/or as conferring a more than 
2-fold change in replication in comparison to the 
wildtype reference strain in in vitro phenotypic assays 
were included in the analysis.
RESULTS
Database search
The search resulted in 831 NS3, 869 NS5A and 6,065 
NS5B sequences from HCV genotypes 1a, 1b, 2a, 2b 
and 3a. After the exclusion of incomplete sequences 
and those containing errors and/or gaps, and from 
patients previously treated with DAA, 798 sequences 
were included in the NS3 dataset. There were 313 
from genotype 1a, 412 from genotype 1b, 19 from 
genotype 2a, 26 from genotype 2b and 28 from 
genotype 3a. There were 699 sequences identified 
in the NS5A dataset, with 272 from genotype 1a, 
353 from genotype 1b, 19 from genotype 2a, 26 
from genotype 2b and 29 from genotype 3a. For the 
NS5B polymerase there were 535 HCV sequences: 
165 from genotypes 1a, 307 from genotype 1b, 19 
from genotype 2a, 24 from genotype 2b and 20 from 
genotype 3a. Notably, the NS5B region has more 
than 5300 incomplete sequences deposited into this 
databank.
Mutation analyses 
Mutation analyses were performed for positions 
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in our dataset. Mutations L23M (0.37%), M28T (0.75%), 
Q30H (1.47%), Q30R (0.37%), L31M (1.12%), P58S 
(2.21%) and Y93C (0.37%) were observed, whereas 
no variants were observed at NS5A position 32. Of 
the 353 subtype 1b sequences analyzed, 0.28% had 
the L23I mutation, 2.27% had L28M mutation, 5.95% 
had R30Q mutation, 3.40% had M31L mutation, 
3.68% had P58S mutation, and 4.25% had the Y93H 
mutation. Of 19 subtype 2a sequences analyzed, one 
(5.26%) sequence had the Q30R mutation, 3 (15.79%) 
sequences had the M31L mutation, and one (5.26%) 
sequence had the H58P mutation. For subtype 2b a 
total of 26 sequences were analyzed, 6 (23.08%) with 
the L31M and one (3.85%) with the S58P mutation. In 
subtype 3a, for which 28 sequences were analyzed, the 
resistant variants M28I, A30L and P58R were found, 
each in a different sequence (3.57%) of the dataset. 
Only M31L was found in more than one sequence 
(23.08%) for this subtype. No mutation was found in 
the NS5A sequence at position 32 of any subtype.
NS5B polymerase inhibitors (Table 3): The NS5B 
S96T, C223H/Y, and S282T variants were not observed 
in any sequence in the present study, and the NS5B 
N142T variant was observed in 0.32% of the subtype 
1b sequences. The V321L RAV was identified in 0.6% 
of genotype 1a sequences and in 0.32% of genotype 
1b sequences.
The C316Y, S556G, and D559N RAVs were identified 
in 0.33%, 7.82% and 0.32% of genotype 1b sequences, 
respectively, and were not observed in other genotypes. 
The M414T and Y448H RAVs were not found in any of 
the 535 NS5B sequences analyzed.
Variants at NS5B positions 495 and 496 known 
to confer resistance polymerase inhibitors were not 
observed; on the other hand, the NS5B A421V and 
V499A substitutions were found in both subtypes 1a 
and 1b. The A421V mutation occurred in 9.64% of 
subtype 1a and in 4.55% of subtype 1b sequences. 
The V499A variant was the dominant amino acid 
substitution in subtype 1a sequences (95.15%), while 
for subtype 1b it was observed in only 9.74% of the 
sequences; there has been no reported evidence for 
negative clinical impact of the V499A. 
where resistance-associated amino acid substitutions 
have been described in the literature for conferring 
resistance to DAA. Amino acid substitutions related to 
HCV resistance to DAA are described below.
Frequency of resistance-associated variants
NS3/4A PI (Table 1): The available PI are more 
effective against HCV genotype 1 than to other 
genotypes due to natural polymorphisms in the NS3 
region of the latter, therefore they are only used in 
the treatment of patients carrying HCV genotype 1. 
Thus, our analysis discusses mainly the findings for 
the genotype 1 dataset; nevertheless, the results for 
the other genotypes are shown in Table 1. The Q80K 
variant was the most prevalent mutation, found in 
44.66% of the subtype 1a, and in 0.25% of subtype 
1b sequences; the variant V80L was also observed in 
6.39% of the latter. Other positions with frequencies 
higher than 2% were I170V (3.21%) in genotype 
1a, and Y56F (15.93%), V132I (23.28%) and I170V 
(65.2%) in genotype 1b.
The V36L and V36M RAVs were identified in 1.6% 
and 0.32% of genotype 1a sequences, respectively, 
and in 0.74% and 0% of genotype 1b, respectively. 
The T54S variant was observed in 0.97% of genotype 
1a and in 0.5% of genotype 1b sequences. The 
R155K variant was observed in 0.64% of genotype 
1a sequences and was not observed in genotype 
1b. There were two genotype 1b sequences (0.5%) 
with P substitution at position 155. Finally, no RAV 
A156T mutation was found in the 831 NS3 sequences 
analyzed.
The prevalence of resistant variants for the PI 
was found to be low in the dataset. Amino acid 
substitutions conferring resistance to these drugs 
were observed at NS3 position 168; the most frequent 
mutation was D168E, which was found in 0.32% of 
subtype 1a and in 0.98% of subtype 1b sequences. 
The prevalence of known NS3 variants enriched for by 
GZR was found to be low: F43S (0.31%) and Y56H 
(0%) in the whole dataset; the NS3 Q41R mutation 
was not observed.
NS5A replication complex inhibitors (Table 2): For 
subtype 1a there were a total of 272 NS5A sequences 
Table 1  Main amino acid substitutions found in the hepatitis C virus NS3 protease 
Amino acid (frequency %)
HCV genotype
1a 1b 2a 2b 3a
Position wt Variants wt Variants wt Variants wt Variants wt Variants
36    V (98.08) L (1.6) M (0.32)  L (0.74)   I (0.25)   V (99.01) L (100) - L (100) - L (100) -
80   Q (54.37)     K (44.66) R (0.97)    Q (93.37) K (0.25) L (6.39) G (100) - G (100) - Q (100) -
155    R (99.36)   K (0.64) -    R (99.50)  P (0.50) - R (100) - R (100) - R (100) -
156 A (100) - - A (100) - - A (100) - A (100) - A (100) -
168    D (99.36)   E (0.32) G (0.32)    D (98.77) A (0.25) E (0.98) D (100) - D (100) - Q (100) -
Amino acids in bold are associated with resistance. wt: Wild-type; HCV: Hepatitis C virus.
Kliemann DA et al . Polymorphisms and resistant mutations in HCV sequences from euHCVdb
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In contrast to NS3 PI, NS5B-non-nucleoside-
inhibitors and NS5A-inhibitors where resistance 
mutations are subtype-dependent, little is known 
about NS5B nucleos(t)ide analogs genotype- and 
subtype-dependent resistance mutations. Several 
nucleotide analogs have shown very promising 
results and SOF is the first DAA in this drug class to 
gain regulatory approval[9,26], followed by DSV. In the 
present analysis, NS5B RAV were not detected in 
genotype 1a, whereas in genotype 1b, NS5B RAV were 
found in more than one third of the individuals (C316N 
in 37.02% and S556G in 7.82%) conferring low to 
medium resistance to DSV. In mixed cohorts consisting 
of American and European patients, while the S556G 
mutation was observed in frequencies of 0.5%-16%, 
the C316N RAVs occurred in frequencies lower than 
that observed in this study (11%-18%), at baseline in 
genotype 1b samples[15].
The S282T is the in vitro signature resistance 
mutation that conveys decreased susceptibility to 
SOF in the replicon system. Although the S282T 
substitution requires only a single nucleotide change, 
this variant was not found in any of the NS5B 
sequences analyzed in this study, neither in a previous 
study based on sequences from the Los Alamos 
databank[11]; in a study that analyzed 1459 HCV 
sequences from GenBank, this mutation was found in 
only one sequence[20].
Table 4  Resistance associated variants conferring resistance to direct antiviral agents1
euHCVdb Los Alamos
1a 1b 1a 1b
DAA RAV RAV RAV RAV
NS3
   Simeprevir  V36M (0.32%)  V36M (0.44%)
   Q80K (44.66%)   Q80L (6.39%)    Q80K (36.62%)   Q80L (6.02%)
S122G (4.49%) S122G (9.07%) n.a n.a
R155K (0.64%) R155K (0.88%)
D168E (0.32%) D168E (0.98%) D168E (0.29%) D168E (0.80%)
D170T (0.20%)
   Paritaprevir R155K (0.64%) R155K (0.88%)
D168E (0.32%) D168E (0.98%) D168E (0.29%) D168E (0.80%)
   Grazoprevir A156T (0.00%) A156T (0.00%) A156T (0.00%) A156T (0.00%)
D168E (0.32%) D168E (0.98%) D168E (0.29%) D168E (0.80%)
NS5A
   Ledipasvir  M28T (0.75%) n.a n.a
 Q30H (1.47%)
 Q30R (0.37%)
 L31M (1.12%)
 Y93H (0.74%) Y93H (4.25%)
 Y93C (0.37%)
   Daclatasvir  M28T (0.75%) n.a n.a
 Q30H (1.47%)
 Q30R (0.37%)
 Y93H (0.74%)   Y93H (4.25%)
   Ombitasvir  M28V (4.49%)   Y93H (4.25%) n.a n.a
   Elbasvir  Q30H (1.47%)
 L31M (1.12%)
 Y93H (0.74%)   Y93H (4.25%)
NS5B
   Sofosbuvir S282T (0.00%) S282T (0.00%) S282T (0.00%) S282T (0.00%)
   Dasabuvir   C316N (37.02%)   C316N (36.17%)
C316Y (0.32%) C316Y (0.30%)
N556G (7.82%) N556G (0.42%) N556G (8.21%)
1DAAs recommended by the EASL and AASLD guidelines 2015. RAV: Resistance associated variants; DAAs: Direct antiviral agents; AASLD: American 
Association for the Study of Liver Diseases.
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Amino acid in bold are associated with resitance. wt: Wild-type; HCV: Hepatitis C virus.
Table 3  Main amino acid substitutions found in the hepatitis C virus NS5A protease
Amino acid (frequency %)
HCV genotype
1a 1b 2a 2b 3a
Position wt wt wt wt wt
282 S 99.40 R 0.60 S S S S
316 C N 37.02 C 62.34 R/Y 0.32 C C C
556 S N 89.24 D   0.98 G 7.82 N 1.95 G G G
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With the currently in-use DAAs recommended by 
EASL and AASLD guidelines, our analyses suggest that 
it is possible that virologic failure could occur in half of 
the patients with HCV genotype 1a receiving SMV in 
combinations with pegylated-intereferon and ribavirin. 
In addition, more than 7% of the patients with HCV 
genotype 1b receiving DSV could also fail to respond to 
treatment, and the presence of variants with resistant 
mutations in the NS5A region should affect almost 5% 
of the treated individuals.
If in one hand the analysis of a public databank 
may not reflect the real prevalence of RAV in the 
population, on the other hand the abundance of infor-
mation deposited in databank’s sequences allows the 
identification of potentially unknown polymorphisms 
in populations not submitted to new HCV treatments. 
Since it is impossible to correlate criteria of inclusion 
in databanks with population data, epidemiological 
studies are necessary to determine the real prevalence 
of RVA in the population.
Although the potential to confer resistance to 
DAAs of the majority of the amino acid substitutions 
identified in our analyses is not known, the ability of 
HCV to rapidly evolve under drug selection pressure 
and the presence of baseline natural polymorphisms 
associated with resistance to DAA should be considered 
as possible threats to the success of these new 
therapies. The real impact of these constitutive RAV 
on the possibility of SVR with DAA remains unclear 
and undefined and some of these RAV apparently 
disappear after therapy (NS3/NS4 RAV) while others 
remain in the viral population (NS5 RAV). Globally, 
clinical significance of these constitutive RAV remains 
obscure
In summary, there are many relevant clinical ques-
tions that still need to be answered regarding HCV 
resistance to DAAs, mainly due to the limited available 
data and the large number of DAA approved or soon 
to be approved for clinical use. Perhaps resistance 
mutations in the new interferon-free DAA era may not 
have significant clinical impact initially[27,28], nonetheless 
the presence of a minor drug-resistance population 
will likely affect the success of the therapy upon the 
expansion and prolonged use of DAA regimens, and 
the relevance of pre-existing resistance mutations for 
responses to Interferon-free DAA therapies needs to 
be further investigated. Therefore, testing for drug 
resistance variants prior to the initiation of treatment 
will be needed in the very near future in order to help 
guide the selection of the most optimized treatment 
option.
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